Home > Resources > Whitepapers > FDA Pharmaceutical Quality Oversight

FDA Pharmaceutical Quality Oversight

The launch of the Center for Drug Evaluation and Research (CDER) Office of Pharmaceutical Quality (OPQ) is a milestone in FDA’s efforts to assure that quality medicines are available to the American public. As a new super-office within CDER, OPQ is strategically organized to streamline regulatory processes, advance regulatory standards, align areas of expertise, and originate surveillance of drug quality. Supporting these objectives will be an innovative and systematic approach to product quality knowledge management and informatics.

Spotlight

Emitac Healthcare Solutions

With more than 40 years of experience in the industry, our integrated team of professionals have deployed several Clinical and IT Solutions in a number of leading government, semi government, Military and private hospitals in the MENA region. With our extensive market knowledge and well established partnerships with some of the world’s leading healthcare and technology providers, we continue delivering the highest standards of quality care. Through our unique combination of workforce empowerment, process improvement and technology optimization, we offer reliable and cost effective solutions to our customers to achieve sustainable results.

OTHER WHITEPAPERS

The colors of life: an interdisciplinary artist-in-residence project to research fungal pigments as a gateway

whitePaper | January 10, 2022

Biological pigmentation is one of the most intriguing traits of many fungi. It holds signifcance to scientists, as a sign of biochemical metabolism and organism-environment interaction, and to artists, as the source of natural colors that capture the beauty of the microbial world.

Your Ultimate Guide to CMC Testing Support for Gene and Cell Therapy

whitePaper | December 6, 2022

The development of Advanced Therapy Medicinal Products such as gene and cell therapy products, has made significant progress in the treatment of many diseases, including cancer, genetic, and autoimmune disorders.

Mainstreaming Cell & Gene Therapies

whitePaper | October 27, 2022

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Osmolality monitoring for UF/DF and CEXcapture of mAbs from mammalian cell cultures

whitePaper | July 25, 2022

The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.